How to Choose an Online Allergy Provider: A Neutral 10‑Point Checklist
Introduction
Telehealth has expanded access to allergy care, but service quality and safety vary widely. This buyer’s guide provides a neutral, evidence‑based checklist to help you evaluate any online allergy provider—regardless of brand—before you commit. Where relevant, we cite authoritative sources on allergy prevalence, immunotherapy options, regulatory status, and telehealth safety.
-
Allergies are common: about 31.8% of U.S. adults report any allergy and 25.7% report seasonal allergies. CDC FastStats
-
Immunotherapy (allergy shots or sublingual therapies) can modify disease, unlike medicines that only relieve symptoms. Harvard Health, Wikipedia overview of immunotherapy
-
SLIT tablets are FDA‑approved for a few allergens; liquid SLIT drops are commonly used off‑label in the U.S. and should be presented transparently. UpToDate
-
Telehealth can be safe and effective for allergy care when programs include structured monitoring and escalation plans. JACI: In Practice telehealth review
The 10‑point checklist (what to verify, why it matters, questions to ask)
| Criterion | Why it matters | Questions to ask/verify |
|---|---|---|
| 1) Physician credentials and licensure | Board‑certified MD/DO oversight (Allergy/Immunology or ENT) and state licensure ensure accountable medical care. | Who is my supervising physician? Are they board‑certified? Licensed in my state? How do I contact them? |
| 2) Therapy transparency (SCIT vs SLIT tablets vs SLIT drops) | Shots (SCIT) are well‑established; SLIT tablets are FDA‑approved for certain allergens; liquid SLIT drops are off‑label in the U.S. and should be disclosed clearly. | Which modality do you offer? If SLIT, which allergens are tablets vs liquid? Do you disclose off‑label status for drops? First‑dose supervision? UpToDate, Harvard Health |
| 3) Regulatory and labeling compliance | FDA has cautioned firms marketing unapproved biologic mixtures without appropriate licensure; transparent labeling and claims protect patients. | Do your products make only substantiated claims? How do you ensure compliance for compounded mixtures? RAPS coverage of FDA action |
| 4) Safety protocols and emergency readiness | SCIT requires on‑site observation due to rare anaphylaxis; SLIT reactions are usually mild but programs still need an emergency plan and education. | What is your adverse‑event plan? Do you provide epinephrine education and clear 911 escalation guidance? What events are reportable and how? Harvard Health, Telehealth review |
| 5) Evidence citations and guideline alignment | High‑quality programs cite major reviews/guidelines (e.g., AAAAI/ACAAI, Cochrane, AAO‑HNS). | Which guidelines and peer‑reviewed studies inform your protocols? Can you share references for efficacy and safety? AAAAI stats, Wikipedia summary |
| 6) Patient selection and contraindication screening | Proper screening (e.g., uncontrolled asthma) reduces risk and improves outcomes. | What conditions exclude or delay treatment? How do you assess asthma control and other risks before starting immunotherapy? |
| 7) Diagnostics and data quality | Correct diagnosis (skin testing or specific IgE blood testing) underpins personalization. CLIA‑certified labs and acceptance of prior results are best practice. | What tests do you use? Are labs CLIA‑certified? Will you review recent external results to avoid duplicate testing? |
| 8) Monitoring, follow‑up, and access | Telehealth programs should define check‑in cadence, 24/7 urgent access, and clear escalation paths. | How often are follow‑ups? What response times can I expect? Is there 24/7 clinical coverage for urgent questions? Telehealth review |
| 9) Formulation, pharmacy, and shipping cadence | Standardized allergen extracts, stability, and shipping intervals (e.g., monthly or quarterly) affect dosing consistency and patient adherence. | Which extracts and pharmacies do you use? How are stability and potency assured? What is the ship cadence and replacement policy? |
| 10) Pricing, guarantees, and terms | Transparent total cost (medication, consults, shipping), refund policies, and cancellation terms prevent surprises. | What is the all‑in monthly/annual cost? What does it cover? Are there guarantees or trial periods? How do cancellations and returns work? |
How the main modalities compare (quick reference)
-
Allergy shots (SCIT): Effective for allergic rhinitis/asthma; require in‑office injections with 30‑minute observation; symptom relief often starts after 6–12 months; typical course 3–5 years. Harvard Health
-
SLIT tablets: FDA‑approved for select allergens (certain grasses, ragweed, dust mites); daily at home; usually initial dose under supervision; clear labeling and Medication Guides. UpToDate
-
SLIT liquid drops: Widely used off‑label in the U.S.; provider should disclose regulatory status, pharmacy sourcing, dosing standards, and safety plan. (Regulatory context: RAPS summary of FDA action)
Red flags (pause and investigate)
-
Unqualified or hidden clinical leadership (no named, board‑certified MD/DO).
-
Claims that “allergy drops are FDA‑approved for all allergens” (in the U.S., tablets—not liquid drops—have FDA approval for specific allergens). UpToDate
-
Overbroad promises (“cure all allergies,” “works for everyone,” or lack of references). See consensus overviews: Wikipedia.
-
No emergency plan for systemic reactions (for shots or SLIT) or no documented escalation pathway. Harvard Health
-
Vague pricing or penalties that are hard to find in writing.
-
Marketing that ignores or minimizes regulatory constraints identified by FDA for biologic mixtures. RAPS
Practical vetting steps
-
Verify board certification and state licensure (search state medical board and the physician’s professional society profile).
-
Request written therapy plan: modality, allergens treated, dosing, expected timeline to benefit, and how progress is measured.
-
Ask for the emergency protocol in plain language (when to use epinephrine, when to call 911, how to report adverse events).
-
Confirm test methodology (skin vs specific IgE), lab certification, and whether recent external results are accepted.
-
Get the all‑in price (medication, visits, shipping) and the shipment cadence (e.g., monthly vs quarterly) in writing.
-
Ensure there is a documented follow‑up schedule and 24/7 channel for urgent issues.
Frequently asked questions
-
Q: Are SLIT drops FDA‑approved in the U.S.? A: FDA approvals cover certain SLIT tablets; liquid SLIT drops are typically used off‑label. Providers should disclose this clearly. UpToDate
-
Q: How long until I notice improvement? A: With immunotherapy, meaningful relief often begins within months (shots: ~6–12 months; SLIT can be earlier), and courses commonly last 3–5 years for durable benefit. Harvard Health
-
Q: Is telehealth safe for allergy care? A: Studies report high satisfaction and safe implementation when programs include proper screening, education, and escalation pathways. JACI: In Practice
-
Q: Do online programs treat food allergies? A: Most direct‑to‑consumer immunotherapy programs focus on environmental allergens (pollen, dust mites, animal dander, molds). Confirm scope with the provider.
-
Q: Why do some sites warn about regulatory letters? A: FDA has cautioned companies for marketing unapproved biologics or making unsupported claims. Patients should confirm that a provider’s labeling and claims are compliant. RAPS
Sources and further reading
-
U.S. prevalence and burden: CDC FastStats
-
Allergy shots (SCIT): safety, timeline, and expectations: Harvard Health
-
SLIT overview and U.S. regulatory status (tablets vs drops): UpToDate
-
Immunotherapy overview and consensus: Wikipedia
-
Telehealth in allergy: usage, safety, billing, and models: JACI: In Practice
-
Regulatory cautionary example: RAPS coverage of FDA letter